Compumedics Limited · ASX:CMP
Compumedics — H1 FY2008 Earnings Presentation
29 slides from Compumedics's earnings presentation, Feb 26, 2008
Slide 1: Business Up-date - 2008 Half-Year Result
Business Up-date - 2008 Half-Year Result COMPUMEDICS ee ne rr ee Defining Life’s Signals
Slide 2: Overview
Over view Capital equipment patient monitoring business (Core business) • Existing business up-date – financial results for 6 months to 31 December 2007 • Step out opportunity - USA ambulatory sleep business • Step out opportunity - Neuvo™ – NEW long-term monitoring device into NEW market for Comp
Slide 3: Core business - Financial update
Core business - Financial update STRENGTHENING financial position and SOUND outlook RECORD profit-after-tax more than triples to $1.6m in the half-year to 31 December 2007 RECORD half-year revenues of $20.1m. Revenues would have been approximately $23m had exchange rates not moved adversely fr
Slide 4: Core Business - Financial update
Core Business - Financial update Gross MARGINS IMPROVE from 59% at 30 June 2007 to 63% at 31 December 2007, despite rising Australian dollar. Gross margins are now 8% higher than at December 2005 when current turnaround strategies were implemented. Operating EXPENSES DECLINE $0.8m or 7% to $11.0
Slide 5: Core Business - Financial update
Core Business - Financial update . BORROWINGS substantially REDUCED from $5.6m at the prior corresponding half-year to $3.1m at the end of the current half- year. The LOWEST level of borrowings in 5 years Borrowing costs at $0.3m were 40% LOWER than the prior corresponding half-year due primaril
Slide 6: Core Business - Financial update
Core Business - Financial update Actual Actual Actual Actual half year half year half year half year Dec 2004 Dec 2005 Dec 2006 Dec 2007 Revenues ($m) 19.4 18.1 19.7 20.1 Margins % 57% 54% 62% 62% Operating Expenses (10.7) (12.9) (11.8) (11.0) Foreign exchange (1.0) - (0.2) (0.3) EBITDA (0.4) (2.1)
Slide 7: Core Business - Financial update (revenues)
Core Business - Financial update Total group revenues at $20m, would have been $22m had the Australian dollar not risen against other currencies and competitive and regular banking services been available Underlying 25 revenue growth at 10% largely 20 washed away by adverse 15 currency AUDm movement
Slide 8: Core Business - Financial update (gross margins)
Core Business - Financial update Gross Margins at 62% are same as prior corresponding half-year and 3% better than at 30 June 2007 despite the rising Australian dollar 62 Product 60 profitability restored 58 % 56 54 52 50 2002 2003 2004 2005 2006 2007 Gross margins for the 6 months to December 31 Sl
Slide 9: Core Business - Financial update (operating expenses)
Core Business - Financial update Operating Expenses continue to decline - $1.9m or 15% over the last two years Sustainable cost 14 base re-affirmed 12 DWL acquisition 10 8 AUDm 6 4 2 0 2002 2003 2004 2005 2006 2007 Expenses for the 6 months to December 31 Slide 9
Slide 10: Core Business - Financial update (EBITDA)
Core Business - Financial update EBITDA record half-year profitability at current revenue levels, which are constrained by the higher Australian dollar 2.5 RECORD EBITDA 2 1.5 1 0.5 AUDm 0 -0.5 -1 -1.5 -2 -2.5 2002 2003 2004 2005 2006 2007 EBITDA for the six months ended December 31 Slide 10
Slide 11: Core Business - Financial update (bank debt)
Core Business - Financial update Bank debt reduction continues – lowest debt levels in 5 years! 8 7 DWL acquisition 6 5 AUDm 4 3 2 1 0 2002 2003 2004 2005 2006 2007 Bank Debt at December 31 Slide 11
Slide 12: Core Business - Financial update (borrowing costs)
Core Business - Financial update Bank costs some respite despite improving business performance and debt repayment. Bank changed January 2008 0.5 0.4 0.3 AUDm 0.2 0.1 0 2002 2003 2004 2005 2006 2007 Borrowing costs for the 6 months to December 31 Slide 12
Slide 13: Core Business - Financial update (foreign exchange)
Core Business - Financial update Foreign exchange impacts adversely again in current half year AUD/USD rate 0.56 0.74 0.78 0.73 0.79 0.88 0 -0.2 -0.4 Exchange movements relate AUDm largely to consolidation of off -0.6 shore group subsidiaries and not appropriate to hedge – almost 90% of the total -0
Slide 14: Business unit revenues
Business unit revenues Business unit revenues improving 9 8 7 6 5 AUDm 4 3 2 1 0 2002 2003 2004 2005 2006 2007 Sleep Brain research EEG/DWL Supplies/Service Revenues by business for the 6 months to December 31 Slide 14
Slide 15: Geographic revenues
Geographic revenues MI Asia 1% Australia Australia 13% 14% Asia 12% 2007 H1 20% 2006 FY DWL DWL 14% 15% Europe 11% MI USA Europe USA Australia 43% Asia 1% 43% 14% 14% 14% DWL 14% USA Europe 42% 15% 2008 H1 MI = Medical innovations Slide 15
Slide 16: Key achievements completed in H1 2008
Key achievements completed in H1 2008 New banking service provider chosen – greater flexibility and less expensive USA office relocated to Charlotte, North Carolina – less expensive New market opportunities in brain research executed with several pharmaceutical companies in the US and Europe
Slide 17: Early H2 2008 performance
Early H2 2008 performance Business performing to plan US brain research business momentum continues, Australian business strong and Asian research business strong, US sleep business picking up. Cost containment continues. Australian dollar still high relative to the US dollar - at top of the
Slide 18: Outlook - financial
Outlook - financial Replication of the first half result in the second half without loosing cost control restraints will be the primary focus With a return to sound business fundamentals the business has the opportunity to continue cash, profit and revenue growth – but will remain cautiously opt
Slide 19: Outlook – CMP annual sales compared to global market annual sales
Outlook – CMP annual sales compared to global market annual sales Sleep diagnostics Brain Research Neuro diagnostics AUD30m AUD250m Global market CMP current sales Global market CMP current sales Supplies AUD890m AUD260m Global market CMP current sales Global market CMP current sales Slide 19
Slide 20: Medical innovation – Sleep treatment
Medical innovation – Sleep treatment Compumedics SPAP™ sleep treatment technology validated to be best of class Immediate deal for $2m of products signed in 2007 OEM discussions for $100m contract potential on-going Major world leading medical gas companies interest with an average market ca
Slide 21: Market valuations – core business only
Market valuations – core business only Shares on issue 142.5m ASX average PE ratio 14 Annualised earnings $3.2m Healthcare equipment 20 and services (HES) sector PE ratio Current share price 12.5 Leading company in 35 cents HES sector PE ratio’s CMP share price at 32 ASX PE ratio cents The valuation
Slide 22: Outlook - technology
Outlook - technology DWL Blood Flow Neuroscan Diagnostics Sleep Diagnostics Neuro Neuro Diagnostics Medical Building a global medical diagnostic company Supplies With Compumedics’ core strategic edge being Sleep Diagnostics Leveraging this technology into related fields including Neurosciences,
Slide 23: Outlook - technology: New Products
Outlook - technology New Products Nexus Profusion PSG 3 Somte PSG Neuvo Slide 23
Slide 24: Outlook - technology
Outlook - technology No other company has the world’s leading technology and/or market position covering 3 of the key rapid growth, new generation medical technology markets first discovered in the 1980s •Clinical Sleep •Transcranial Doppler (TCD) •Computerised Cognitive Neuroscience/EEG brain funct
Slide 25: Outlook - technology: Sleep Market
Outlook - technology Sleep Market Pioneering of computerised PSG (CMP;1987) and CPAP treatment discovery [Sullivan, CE (1981), Sydney Australia] 40% of the Australian Clinical EEG Market and 70% of the Australian Sleep Diagnostics Market. 10% USA market share and growing in Sleep Heart Health
Slide 26: Outlook - technology: Transcranial Doppler Market
Outlook - technology Transcranial Doppler (TCD) Market Developed by Dr. Rune Aaslid in 1982, today DWL’s client DWL has a strong market share in Germany and well established distribution networks in Europe World’s firsts include : Q Bilateral Doppler , Q Emboli differentiation Q Full digital D
Slide 27: Outlook - technology: Cognitive Neuroscience/EEG
Outlook - technology Computerised Cognitive Neuroscience/EEG brain function Pioneered by Neuroscan in 1989 Commands 90% of the US Market for Research EEG applications and a significant market share worldwide. Sells its products in over 50 countries worldwide to over 1500 universities, corporat
Slide 28: Business Recap
Business Recap Profits triple from prior corresponding half-year despite rising Australian dollar and the adverse impact this has on revenues and margins Operating cash flow more than doubles compared to prior corresponding half-year Cost vigilance to remain R&D product pipeline strong – new
Slide 29: Thankyou
Thankyou of SLEE Y ee rap . 1 DIAGNOSTIC ‘Nyafinin T jfo’e Signal’ Ao Sib esd Vetining Lijes signals EXCELLENCE . a 1987 - 2007